Is Lipoxin A4 an Effective Treatment on Fat Embolism Syndrome by Attenuating Pro-Inflammatory Response?

Hui Zhang,Aizhong Wang,Tao Xu,Junfeng Zhang,Wei Jiang,Fangfang Niu,Hong Xie
DOI: https://doi.org/10.1016/j.mehy.2018.11.019
IF: 4.7
2019-01-01
Medical Hypotheses
Abstract:Fat embolism syndrome (FES) is characterized by high mortality and lack of effective treatment, the symptomatic therapy is most used to relieve clinical symptoms. Some studies have shown that inflammation is one of the main pathogeneses of FES. Lipoxin A4 is an endogenous-derived anti-inflammatory substance which was discovered recently. It can alleviate inflammatory response and promote inflammation resolution, and is referred as brake signal of inflammation. Therefore we hypothesize that lipoxin A4 may have a remission and therapeutic effect on FES by attenuating FES-induced inflammatory responses.
What problem does this paper attempt to address?